Effects of combined therapy on the time course of the articular syndrome in patients with psoriasis in the presence of lipid metabolism disorders


Cite item

Full Text

Abstract

The prevalence and incidence ofpsoriatic disease in the Russian Federation remain high. One of the most severe disabling forms ofpsoriatic disease is psoriatic arthropathy (PA) - chronic inflammatory seronegative spondyloarthropathy with the predominant involvement of the distal interphalangealjoints of the hands, metatarsophalangeal articulations, and of the spine, combined with skin manifestations ofpsoriasis. Metabolic disorders are highly incident in the patients with PA, this augmenting cardiovascular risk. Search for approaches to improving the available effective pathogenetic therapies for PA with due consideration for the metabolic (including lipid metabolic) disorders is therefore an important problem. We studied the effects of combined therapy including simvastatin on the time course of the articular syndrome and functional status of 91 PA patients with lipid metabolism disorders.

About the authors

Andrey Igorevich Yakubovich

Irkutsk State Medical University

Email: divanand@mail.ru
MD, PhD, D.Sc, prof. Irkusk, Russia

Ludmila Sergeevna Saldamaeva

Ust-Orda Regional Center of Skin and Sexually-Transmitted Diseases

Email: d.saldamaeva@mail.ru
врач-дерматовенеролог первой категории 669001, Ust-Ordinskiy, Irkutsk region, Russia

References

  1. Знаменская Л.Ф., Мелехина Л.Е. Заболеваемость и распространенность псориаза в Российской Федерации. Вестник дерматологии и венерологии. 2012; 5: 20-9. [Znamenskaya L.F., Melekhina L.E. The incidence and prevalence of psoriasis in the Russian Federation. Vestnik dermatologii i venerologii. 2012; 5: 20-9]
  2. Papp K., Langley R.G., Lebwohl M. Efficacy and safety of ustekinumab, a human IL-12/23 monoclonal antibody, in patients with psoriasis:52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008; 371(9625): 1665-74.
  3. Ritchlin C.T. The pathogenesis of psoriasis andpsoriatic arthritis. New application for TNF inhibition. Immunex. Philadelphia; 2000: 9-20.
  4. Кочергин Н.Г. Псориаз: коморбидности и комедикации. Врач. 2009; 5: 15-20. [Kochergin N.G. Psoriasis: comorbidity and comedication. Vrach. 2009; 5: 15-20]
  5. Кочергин Н.Г, Смирнова Л.М. Последние тренды в лечении псориаза. Лечащий врач. 2005; 5: 37-9. [Kochergin N.G., Smirnova L.M. Last trends in the treatment of psoriasis. Lechashchiy vrach. 2005; 5: 37-9]
  6. Giardina E., Sinibaldi C., Novelli G. Mapping the future of common diseases: lessons from psoriasis. Front. Biosci. 2007; 12: 1563-73.
  7. Taylor W., Gladman D., Helliwell P., Marchesoni A., Mease P., Mielants H.; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arth. Rheum. 2006; 54(8): 2665-73.
  8. Gottlieb A.B., Evans R., Li S., Dooley L.T., Guzzo C.A., Baker D., et al. Infliximab induction therapy for patients with severe plague-type psoriasis: a randomized, double- blind, placebocontrolled trial. J. Am. Acad. Dermatol. 2004; 51(4): 534-42.
  9. Myers W.A., Gottlieb A.B., Mease P. Psoriasis and psoriatic arthritis:clinical features and disease mechanisms. Clin. Dermatol. 2006; 24(5): 438-47.
  10. Likert R.A. Technigue for a meas of attitudes. Arch. Psychol. 1932; 7(40): 20-5.
  11. Агабабова Э.Р., Бадокин В.В., Эрдес Ш. Разработка и апробация диагностических критериев псориатического артрита. Тер. арх. 1989; 12: 117-21. [Agababova E.R., Badokin V.V., Erdes Sh. Development and testing of diagnostic criteria for psoriatic arthritis. Terapevticheskiy arkhiv. 1989; 12: 117-21.]
  12. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin. Chem. 1972; 18(6): 499-502.
  13. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации (IV пересмотр). Кардиоваскулярная терапия и профилактика. 2009; 6(Приложение 3). [Diagnosis and correction of lipid disorders for the prevention and treatment of atherosclerosis. Russian recommendations: IV revision. Kardiovaskulyarnaya terapiya i profilaktika. 2009; 6(Suppl. 3)]
  14. Fredrickson D.S., Lee R.S. A systems for fhenotyping hyperlipidemia. Circulation. 1965; 31: 321-7.
  15. Clegg D.O., Reda D.J., Mejias E., Cannon G.W., Weisman M.H., Taylor T., et al. Comparison of sulfasalasine and placebo in the treatment of psoriatic arthritis: a Departament Veterans Affairs Cooperative Study. Arthritis Rheum. 1996; 39(12): 2013-20.
  16. Ropes M.W., Bennet G.A., Gobb S., et al. Revision of diagnostic criteria for rheumatoid arthritis. Bull. Rheum. Dis. 1958; 9(4): 175-6.

Copyright (c) 2014 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies